![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Hangzhou Huadong Medicine Group Zhejiang Huayi Pharmaceutical Co., Ltd. Yiwu Cn, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Ciprofloxacin Hydrochloride, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2006-045 - Rev 01
This Chemical Type CEP, issued on January 11, 2018, remains in force until May 16, 2024, ensuring its reliability within the pharmaceutical industry.
Substance Number 888 associated with this CEP further emphasizes